On Soin et Nature, discover Biogaran’s commitment—a French pharmaceutical company recognized for the quality, safety, and affordability of its generic drugs and health products. Drawing on its expertise and high standards, Biogaran offers reliable solutions to meet everyday therapeutic needs and ensure broader access to healthcare.
More details
Founded in 1996, Biogaran has become, in just a few decades, a major player in the French pharmaceutical industry. Specializing in generic drugs, it offers a reliable and cost-effective alternative to brand-name treatments, while ensuring the highest standards of quality and safety. Since its inception, Biogaran has established itself as a trusted brand, thanks to its commitment to patients and its forward-thinking approach.
The company does not limit itself to generic drugs. Recognizing the diverse needs in the field of health, it also develops dietary supplements and cosmetics, offering a wide range of solutions tailored to consumer expectations. “Innovate to provide better care”—that is Biogaran’s motto, which places effectiveness and accessibility at the heart of its mission.
Biogaran stands out for its local production, with nearly 90% of its medications manufactured in Europe, more than half of which are produced in France. This strategic choice not only ensures better traceability but also significantly reduces its environmental impact. By relying on nearby production sites, Biogaran limits transportation and thus reduces its CO2 emissions.
As part of its environmental commitment, the company has adopted concrete measures, particularly in line with COP21 and the Paris Agreement. The goal is ambitious: to reduce its overall CO2 emissions by 25% by 2030. This effort is part of a comprehensive approach to environmental responsibility, in line with the growing expectations of patients concerned about their health and that of the planet.
A generic drug is a pharmaceutical product that contains the same active ingredient, the same dosage, and is administered in the same way as a brand-name drug, but at a more affordable price. These drugs undergo rigorous testing to ensure their therapeutic efficacy and safety. Biogaran goes beyond regulatory requirements to offer patients products that meet the highest quality standards.
The generic drugs developed by Biogaran provide an accessible and reliable treatment option for many conditions, while helping to reduce healthcare costs. Their lower price makes healthcare more widely accessible—a priority for a pharmaceutical company that is firmly committed to putting people first.
Biogaran is also a pioneer in the field of biosimilar drugs, which it has been developing since 2015. These biologic drugs, produced from living cells, replicate the therapeutic effects of reference treatments. Thanks to their more competitive pricing, they generate substantial savings, which are reinvested in innovation and the improvement of healthcare.
With biosimilars, Biogaran has established itself as an essential partner for hospitals, doctors, and pharmacists, offering modern solutions tailored to patients’ current needs.
Biogaran is not limited to a single area of expertise. By diversifying its offerings, the company meets the varied needs of patients, whether in medical treatment, wellness, or prevention.
Biogaran does more than just provide quality products. The laboratory also supports patients with practical tools and innovative services. For example, educational resources and personalized advice are available to help cancer patients better manage their treatment.
Initiatives such as “Eating Better While Living with Cancer” and “Staying Active While Fighting Cancer” perfectly illustrate this commitment. These resources offer concrete solutions to improve nutrition,physical activity, and mental well-being during treatment.
Biogaran also plays a crucial role in the French economy, supporting 8,600 direct and indirect jobs and collaborating with 40 partner production sites. This model helps strengthen France’s healthcare sovereignty by ensuring optimal product availability. With a 94.6% availability rate, Biogaran ensures that patients have uninterrupted access to their treatments.
